Radioligand therapy with 177Lu-DOTA-PSMA in metastatic castration-resistant prostate cancer. Pharmacokinetics, safety, antitumour efficacy

В. Крылов �, В.; С. Легкодимова, Н.; Ю. Кочетова, Т.; М. Петриев, В.; А. Сигов, М.; К. Тищенко �, В.; И. Пронинм �, А.; Ю. Шуринов, А.; М. Петросян, К.; Н. Спиченкова, О.; Б. Карякин �, О.; А. Бирюков �, В.; Федорович Степаненко, Валерий; П. Власова, О.; Шегай, П.В.; А. Иванов, С.; А.Д.Каприн, �; ValeriyV.Krylov, �.; Legkodimova, N.; TatianaYu.Kochetova, �.; VasiliyM.Petriev, �.; MichailA.Sigov, �.; ViktoriaK.Tishchenko, �.; ArtemI.Pronin, �.; AndreyYu.Shurinov, �.; KarinaM.Petrosyan, �.; Spichenkova, O.N.; OlegB.Karyakin, �.; VitaliyA.Biryukov, �.; F. Stepanenko, V.; OksanaP.Vlasova, �.; PetrV.Shegaj, �.; SergeyA.Ivanov, �.; AndreyD.Kaprin, �.; Krylov V.V., Legkodimova; Kochetova T.Yu., Petriev; V.M., Sigov; Karyakin O.B., Biryukov

doi:10.22328/2079-5343-2022-13-4-75-85

Public

Radioligand therapy with 177Lu-DOTA-PSMA in metastatic castration-resistant prostate cancer. Pharmacokinetics, safety, antitumour efficacy

Shared by NobleBlocks on Jan 17, 2023 • 12:00 AM UTC

Authors:

В. В. Крылов �

Н. С. Легкодимова

Т. Ю. Кочетова

Abstract

INTRODUCTION: The results of studies of clinical potential of a new domestic radiopharmaceutical 177Lu-DOTA-PSMA in patients with metastatic castration-resistant prostate cancer are presented in this article.OBJECTIVE: The pharmacokinetics, safety and tolerability of radiopharmaceutical were studied...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!